2025-09-19 - Analysis Report
Okay, here's an analysis of Schrodinger Inc. (SDGR) based on the data provided. The report will be in English, focusing on key numbers first, followed by analysis.

**Schrodinger Inc. (SDGR) Analysis**

**Company Overview:** Schrodinger Inc. is a company that develops software for drug discovery and materials science.

**1. Performance vs. S&P 500 (VOO)**

*   **SDGR Cumulative Return:** -53.41%
*   **VOO Cumulative Return:** 62.11%
*   **Absolute Divergence:** -115.53% (SDGR lagged VOO by this amount)
*   **Divergence Range:** Max: 66.2, Min: -116.6, Current: -116.6
*   **Relative Divergence:** 0.0 (Indicates SDGR is at the lowest end of its historical divergence range compared to VOO.)

**Alpha/Beta Analysis Table**

| Year       | CAGR   | MDD   | Alpha  | Beta  | Cap(B) |
|------------|--------|-------|--------|-------|--------|
| 2020-2022  | -74.0% | 68.9% | -89.0% | -0.1 | 1.4    |
| 2021-2023  | -65.0% | 68.9% | -83.0% | -0.0 | 2.6    |
| 2022-2024  | 8.0%  | 72.4% | -17.0% | -0.0 | 1.4    |
| 2023-2025  | 0.0%  | 74.0% | -58.0% | -0.0 | 1.4    |

**Analysis:**

*   **Significant Underperformance:** SDGR has significantly underperformed the S&P 500 (VOO) over the period. The negative divergence highlights this stark difference. The relative divergence being at 0.0 suggests this underperformance is at its historical worst within the provided timeframe.
*   **Alpha:** Negative alpha across all periods indicates SDGR consistently underperforms relative to the S&P 500, even considering market risk (beta).
*   **Beta:** Beta values are very close to zero, suggesting SDGR's price is not closely correlated with overall market movements (S&P 500). This might indicate that SDGR's performance is driven by factors specific to the company or its sector rather than broad market trends.
*   **MDD:** High Maximum Drawdown (MDD) figures indicate significant price volatility and potential risk for investors.
*   **CAGR:** The negative CAGR values from 2020-2023 showcase a huge decline in the company.

**2. Recent Price Action**

*   **Current Price:** \$19.65
*   **Previous Close:** \$19.03
*   **Change:** 3.26% (Signaling a sharp increase)
*   **5-day Moving Average:** 18.96
*   **20-day Moving Average:** 19.26
*   **60-day Moving Average:** 20.20

**Analysis:**

*   **Recent Uptick:** The price has risen significantly compared to the previous close, breaking above the 5-day and 20-day moving averages.
*   **Still Below 60-day MA:** The price is still below the 60-day moving average, suggesting the longer-term trend may still be downward or neutral.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.3324 (Low Risk)
*   **RSI:** 48.95 (Neutral - neither overbought nor oversold)
*   **PPO:** 0.40 (Positive, but low, indicating a slight upward trend in momentum)
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (2 shares - Caution - MRI:0.33) (Cash Ratio: 0% on 2025-09-04)
*   **Delta_Previous_Relative_Divergence:** -0.5 (Negative - Short-term decline in relative performance)
*   **Expected Return (%):** -5882.4 (Very large negative value - indicates significant underperformance relative to S\&P 500 if investing for the long term.)

**Analysis:**

*   **Low Market Risk:** MRI indicates a low market risk environment.
*   **Neutral Momentum:** RSI suggests neutral momentum.
*   **Slight Momentum:** PPO suggests slight positive change in momentum.
*   **Hybrid Signal:** suggests caution
*   **Divergence:** The negative change in relative divergence suggests short-term underperformance compared to the benchmark.
*   **Expected Return:** A very large negative expected return suggests caution.

**4. Recent News & Significant Events**

*   **Inducement Grants:** Schrodinger reported inducement grants under Nasdaq rules.
*   **Analyst Opinions (Argus Research):** An article discusses what Argus Research has to say about SDGR.
*   **Valuation Evaluation (Simply Wall St.):** An article evaluates Schrodinger's valuation as market sentiment remains quiet.
*   **Rally Potential (Zacks):** An article discusses the potential for SDGR to rally.
*   **Conference Presentation:** Schrodinger presented at the Morgan Stanley Global Healthcare Conference.

**Analysis:**

*   **Mixed News:** The news is a mixed bag. Inducement grants are typically a neutral to slightly positive sign. Analyst opinions and valuation evaluations could provide insights into the stock's potential. The article about rally potential is positive, but should be viewed cautiously.

**4-2. Analyst Opinions**

*   **Consensus:** Strong Buy (Mean: 1.38)
*   **Opinions:** 9
*   **Target Price (avg/high/low):** \$28.11 / \$33.00 / \$19.00
*   **Recent Rating Changes:** No recent changes indicated in the provided data.

**Analysis:**

*   **Strong Buy Consensus:** Analysts generally have a positive outlook on the stock.
*   **Target Price:** The average target price suggests significant upside potential from the current price. However, there is a wide range between the high and low targets.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-08-06 | -0.59 | 0.05 B\$  |
| 2025-05-07 | -0.82 | 0.06 B\$  |
| 2024-11-12 | -0.52 | 0.04 B\$  |
| 2024-07-31 | -0.74 | 0.05 B\$  |
| 2025-08-06 | -0.74 | 0.05 B\$  |

**Analysis:**

*   **Consistent Losses:** Schrodinger has consistently reported negative EPS (losses) over the recent quarters.
*   **Stable Revenue:** Revenue has been relatively stable, but not enough to offset expenses.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-06-30   | \$0.05B  | 47.77%        |
| 2025-03-31   | \$0.06B  | 52.26%        |
| 2024-12-31   | \$0.09B  | 72.61%        |
| 2024-09-30   | \$0.04B  | 50.24%        |
| 2024-06-30   | \$0.05B  | 66.20%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE     |
|--------------|----------|---------|
| 2025-06-30   | \$0.34B  | -12.59% |
| 2025-03-31   | \$0.37B  | -16.01% |
| 2024-12-31   | \$0.42B  | -9.54%  |
| 2024-09-30   | \$0.45B  | -8.49%  |
| 2024-06-30   | \$0.47B  | -11.40% |

**Analysis:**

*   **Relatively High Profit Margins:** The company maintains high profit margins despite the low revenue. This may suggest a focus on high-value clients or services.
*   **Declining Equity:** Equity has been declining over the recent quarters.
*   **Negative ROE:** Negative Return on Equity (ROE) is consistent with the negative earnings.

**7. Overall Summary**

Schrodinger (SDGR) presents a mixed picture. Here's a summary:

*   **Negative Performance:** SDGR has significantly underperformed the S\&P 500, and its expected return is quite low.
*   **Financial Concerns:** The company reports consistent losses (negative EPS) and declining equity. While it maintains relatively high profit margins, revenue is not high enough to achieve profitability.
*   **Mixed Technicals:** The technical indicators suggest a recent short-term price increase.
*   **Analyst Optimism:** Despite financial concerns, analysts have a "Strong Buy" consensus and suggest significant upside potential. This may be based on the company's long-term prospects, technology, or potential for future growth.
*   **Catalysts:** Focus on the recent news and analyst opinions
*   **Risk:** Investing in SDGR appears to be high-risk given its financial performance and historical underperformance, but there may be potential for high reward if the company can turn around its financials and execute its growth strategy.

**Disclaimer:** *This analysis is based on the provided data and should not be considered financial advice. Investors should conduct their own thorough research before making any investment decisions.*
